Latest news with #Kenvue
Yahoo
16 hours ago
- Business
- Yahoo
JNJ's Consistent Payout Makes It a Top Pick for Down Markets
Johnson & Johnson (NYSE:JNJ) is among the best dividend stocks for a bear market. The company is facing a combination of slow revenue growth, unresolved legal battles over talc products, and looming drug price negotiations under new Medicare rules. These issues could weigh on investor sentiment and profitability in the near term. A smiling baby with an array of baby care products in the foreground. Despite current challenges, Johnson & Johnson (NYSE:JNJ) has a long history of managing legal and regulatory hurdles while maintaining strong performance. With a solid credit rating and the 2023 spinoff of its slower-growth Kenvue unit, the company is better positioned to focus on higher-growth areas and drive future earnings. Johnson & Johnson (NYSE:JNJ) stands out as a top-tier dividend stock, with 63 consecutive years of dividend increases, an impressive track record that highlights the strength and resilience of its core business. This consistency is a key reason why investors continue to favor the stock, even amid current challenges. The dividend remains secure, supported by J&J's strategic focus on innovation in pharmaceuticals and medical devices. The company boasts a robust pipeline of experimental drugs and is advancing cutting-edge technologies like the Ottava robotic surgery system, which could unlock significant long-term growth potential. Johnson & Johnson (NYSE:JNJ) currently offers a quarterly dividend of $1.30 per share and has a dividend yield of 3.45%, as of June 17. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
Yahoo
2 days ago
- Business
- Yahoo
JNJ's Consistent Payout Makes It a Top Pick for Down Markets
Johnson & Johnson (NYSE:JNJ) is among the best dividend stocks for a bear market. The company is facing a combination of slow revenue growth, unresolved legal battles over talc products, and looming drug price negotiations under new Medicare rules. These issues could weigh on investor sentiment and profitability in the near term. A smiling baby with an array of baby care products in the foreground. Despite current challenges, Johnson & Johnson (NYSE:JNJ) has a long history of managing legal and regulatory hurdles while maintaining strong performance. With a solid credit rating and the 2023 spinoff of its slower-growth Kenvue unit, the company is better positioned to focus on higher-growth areas and drive future earnings. Johnson & Johnson (NYSE:JNJ) stands out as a top-tier dividend stock, with 63 consecutive years of dividend increases, an impressive track record that highlights the strength and resilience of its core business. This consistency is a key reason why investors continue to favor the stock, even amid current challenges. The dividend remains secure, supported by J&J's strategic focus on innovation in pharmaceuticals and medical devices. The company boasts a robust pipeline of experimental drugs and is advancing cutting-edge technologies like the Ottava robotic surgery system, which could unlock significant long-term growth potential. Johnson & Johnson (NYSE:JNJ) currently offers a quarterly dividend of $1.30 per share and has a dividend yield of 3.45%, as of June 17. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
13-06-2025
- Business
- Time of India
Kenvue mulls sale of some skin health and beauty brands, sources say
Kenvue is exploring the sale of some of its skin health and beauty brands , four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment to focus on core products. The company, which was spun out of Johnson & Johnson in 2023, is zeroing in on smaller brands in the unit to sell such as Clean & Clear , Maui Moisture , Neostrata, its German baby care brand Bebe, and Japanese brand , the sources said. It plans to hold onto the bigger names in the unit, such as Neutrogena and Aveeno , the sources said. There are about a dozen brands in the skin health and beauty unit, and sources cautioned that the divestiture package could change and no deal was guaranteed. Investment bankers at Goldman Sachs are working with Kenvue on the divestment process, they added. Kenvue and Goldman declined to comment. The around half-dozen brands earmarked for sale would generate more than $500 million of revenue together, two of the sources said, a small portion of Kenvue's overall revenue, which was $15.5 billion in 2024. The skin health and beauty unit has been a drag on Kenvue's earnings, but the company has dedicated more money to marketing, especially on Neutrogena ad campaigns. The unit's organic sales declined 4.8% year-over-year in Kenvue's latest quarter that ended March 30. Kenvue, which also makes Tylenol and Band-Aids, has faced activist pressure over the last year from Starboard Value, Toms Capital Management and Third Point. It settled with Starboard in March, when it added the investment firm's founder to its board. Some of the activists have been pushing the company to consider selling itself or certain brands. In May, the company brought on new Chief Financial Officer Amit Banati from Kellanova, Kellogg's spun-out snacking unit.
Bloomberg
12-06-2025
- Business
- Bloomberg
Kenvue Is Considering Selling Some Brands, Reuters Reports
Kenvue Inc., the consumer-health business that was part of Johnson & Johnson, is exploring a sale of some of its skin-care and beauty brands, Reuters reported Thursday, citing people familiar with the matter. The company may sell brands including Clean & Clear, Maui Moisture and Neostrata, according to Reuters, while holding onto bigger brands such as Neutrogena and Aveeno.
Reuters
12-06-2025
- Business
- Reuters
Kenvue mulls sale of some skin health and beauty brands, sources say
NEW YORK, June 12 (Reuters) - Kenvue (KVUE.N), opens new tab is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment to focus on core products. The company, which was spun out of Johnson & Johnson (JNJ.N), opens new tab in 2023, is zeroing in on smaller brands in the unit to sell such as Clean & Clear, Maui Moisture, Neostrata, its German baby care brand Bebe, and Japanese brand the sources said. It plans to hold onto the bigger names in the unit, such as Neutrogena and Aveeno, the sources said. There are about a dozen brands in the skin health and beauty unit, and sources cautioned that the divestiture package could change and no deal was guaranteed. Investment bankers at Goldman Sachs (GS.N), opens new tab are working with Kenvue on the divestment process, they added. Kenvue and Goldman declined to comment. The around half-dozen brands earmarked for sale would generate more than $500 million of revenue together, two of the sources said, a small portion of Kenvue's overall revenue, which was $15.5 billion in 2024. The skin health and beauty unit has been a drag on Kenvue's earnings, but the company has dedicated more money to marketing, especially on Neutrogena ad campaigns. The unit's organic sales declined 4.8% year-over-year in Kenvue's latest quarter that ended March 30. Kenvue, which also makes Tylenol and Band-Aids, has faced activist pressure over the last year from Starboard Value, Toms Capital Management and Third Point. It settled with Starboard in March, when it added the investment firm's founder to its board. Some of the activists have been pushing the company to consider selling itself or certain brands. In May, the company brought on new Chief Financial Officer Amit Banati from Kellanova(K.N), opens new tab , Kellogg's spun-out snacking unit.
